Interpersonal Therapy (IPT): Four Problem Areas, Efficacy for Depression, and Clinical Adaptations (IPT-A, IPT-G)

Interpersonal Therapy (IPT) is a time-limited, manualized psychotherapy originally developed by Gerald Klerman and Myrna Weissman in the 1970s and 1980s for the treatment of major depressive disorder (MDD). It emerged from the New Haven–Boston Collaborative Depression Research Project and was first fully described in the 1984 manual Interpersonal Psychotherapy of Depression. Unlike psychodynamic therapies from which it partially derives, IPT is focused, structured, and explicitly avoids interpretation of unconscious conflict. Unlike cognitive-behavioral therapy (CBT), it does not target cognitive distortions or assign behavioral homework. Instead, IPT rests on a distinctive theoretical premise: that depression occurs in an interpersonal context, and that resolving interpersonal difficulties—regardless of their etiological primacy—is a powerful lever for symptom remission.

The theoretical lineage of IPT draws from three traditions. First, the attachment theory of John Bowlby, which posits that disruptions in close affectional bonds generate distress and psychopathology. Second, the interpersonal school of psychiatry pioneered by Harry Stack Sullivan, Adolf Meyer, and later Frieda Fromm-Reichmann, which emphasized the social-relational matrix of mental illness. Third, the empirical epidemiological work linking life events—particularly loss, social isolation, and role transitions—to the onset and maintenance of depressive episodes. This epidemiological grounding is what distinguishes IPT from purely psychodynamic approaches: IPT treats the interpersonal precipitant, not the personality structure.

IPT has achieved the status of an empirically supported treatment (EST) for MDD in virtually every major treatment guideline, including those from the American Psychiatric Association (APA), the National Institute for Health and Care Excellence (NICE), and the World Health Organization (WHO). In fact, the WHO includes IPT alongside CBT in its mhGAP Intervention Guide as a recommended psychological treatment for depression in primary care and low-resource settings. IPT has now been adapted for a wide range of disorders, populations, and delivery formats, making it one of the most versatile evidence-based psychotherapies available.

The structural heart of IPT is its case formulation around one or two of four defined interpersonal problem areas. During the initial phase of treatment (sessions 1–3), the therapist conducts an interpersonal inventory—a systematic review of the patient's current and recent significant relationships—and links the onset or exacerbation of depressive symptoms to one or two of the following problem areas:

1. Grief (Complicated Bereavement)

This problem area applies when the depressive episode is associated with the death of a significant person and the mourning process has been abnormal—either delayed, distorted, or absent. In IPT, grief is distinguished from normal bereavement by the persistence and severity of depressive symptoms beyond what is culturally expected, and by evidence that the patient has been unable to complete the mourning process. The therapeutic strategy involves facilitating the expression of affect related to the loss, reconstructing the relationship with the deceased in its full ambivalence (both positive and negative aspects), and helping the patient re-engage with new relationships and activities. It is worth noting that DSM-5-TR removed the bereavement exclusion from MDD diagnosis, and the new diagnostic entity of Prolonged Grief Disorder (PGD) in DSM-5-TR provides additional diagnostic clarity. IPT for complicated grief overlaps with but is not identical to specialized treatments for PGD, such as Complicated Grief Treatment (CGT) developed by M. Katherine Shear.

2. Role Disputes

Role disputes refer to conflicts with a significant other—a spouse, partner, family member, friend, or colleague—where the patient and the other person have nonreciprocal expectations about the relationship. This is the most commonly identified problem area in clinical practice, present in approximately 30–50% of IPT cases. The therapist helps the patient identify the dispute, determine its stage (renegotiation, impasse, or dissolution), and develop strategies for communication and expectation management. The therapeutic focus is on understanding the patient's communication patterns, role expectations, and capacity for assertion. A dispute at impasse requires the therapist to help the patient move toward either renewed negotiation or conscious acceptance of dissolution.

3. Role Transitions

Role transitions encompass life changes that require the patient to adapt to a new social role—such as divorce, retirement, job loss, new parenthood, relocation, diagnosis of a medical illness, or the transition to college. The depressive episode is formulated as arising from difficulty mourning the loss of the old role, managing the affects associated with change, and developing the skills and social supports needed for the new role. Role transitions are the second most commonly identified problem area, accounting for roughly 25–35% of IPT formulations. This category is particularly relevant for perinatal depression, where the transition to motherhood or fatherhood is the focus.

4. Interpersonal Deficits (Interpersonal Sensitivities)

This problem area—sometimes now called interpersonal sensitivities in updated formulations—applies when the patient presents with a history of impoverished or unsustaining relationships, social isolation, and chronic difficulty forming and maintaining connections. It is the least common focus in research samples (approximately 10–15% of cases) and is considered the most challenging to treat within the IPT framework, as it most closely approximates characterological difficulties. The therapeutic approach involves reviewing past relationship patterns, building social skills, and reducing isolation. Notably, research suggests that patients formulated under interpersonal deficits tend to have somewhat poorer outcomes compared to those in other problem areas, a finding that has prompted some IPT theorists to re-conceptualize this category to focus more on sensitivity to interpersonal slights and rejections rather than on a deficit model.

The selection of a problem area is not merely a diagnostic exercise—it determines the therapeutic strategy for the middle phase of treatment (sessions 4–12 in standard 16-session IPT). This focus provides therapeutic clarity and permits the patient and therapist to measure progress against a concrete interpersonal goal.

Standard IPT for MDD is a 12–16 session treatment delivered weekly, divided into three phases:

Initial Phase (Sessions 1–3)

The therapist assigns the patient the "sick role"—a concept borrowed from Talcott Parsons' medical sociology—which legitimizes the patient's current impairment, reduces guilt, and mobilizes the patient to engage in treatment as one would for a medical illness. The therapist conducts a diagnostic evaluation, provides psychoeducation about depression as a treatable medical condition, completes the interpersonal inventory, and collaboratively identifies one (occasionally two) problem area(s) as the treatment focus. A key IPT technique is the explicit linking of mood to interpersonal events, often through the use of a timeline showing the relationship between life events and symptom onset.

Middle Phase (Sessions 4–12/13)

The therapist employs problem-area-specific strategies. Core IPT techniques used across all problem areas include: communication analysis (detailed, almost scene-by-scene reconstruction of interpersonal interactions to identify communication failures), exploration of affect (helping patients identify, tolerate, and express emotions), role-playing (rehearsing new interpersonal behaviors), and decision analysis (weighing options in interpersonal situations). The therapist maintains an active, supportive, and encouraging stance—distinct from the interpretive neutrality of psychodynamic therapy and the more structured, Socratic style of CBT.

Termination Phase (Sessions 13/14–16)

The therapist reviews progress, consolidates gains, explicitly addresses the ending of the therapeutic relationship as itself a managed interpersonal event, and helps the patient anticipate future vulnerabilities. IPT's time-limited nature means that termination is framed from the outset, and the ending can serve as a corrective experience around loss and separation. For patients with recurrent depression, the therapist may recommend maintenance IPT (IPT-M), typically delivered monthly.

The entire therapeutic posture of IPT is characterized by what Weissman, Markowitz, and Klerman describe as an emphasis on the here and now of interpersonal relationships rather than on past developmental history, on affect and interpersonal functioning rather than cognition, and on interpersonal communication rather than intrapsychic structure.

While IPT was developed as an atheoretical, pragmatic treatment, a growing body of research has begun to elucidate the neurobiological pathways through which interpersonal interventions may exert their antidepressant effects. These mechanisms converge on several key systems:

Hypothalamic-Pituitary-Adrenal (HPA) Axis Regulation

Interpersonal stressors—particularly social rejection, loss, and chronic relational conflict—are among the most potent activators of the HPA axis stress response. Elevated cortisol and blunted diurnal cortisol rhythms are well-documented in MDD. Social buffering—the stress-mitigating effect of supportive relationships—operates in part through the attenuation of HPA axis reactivity. IPT's emphasis on resolving interpersonal conflicts and strengthening social support may normalize HPA axis function. Preliminary evidence suggests that successful psychotherapy, including IPT, is associated with reductions in cortisol levels and normalization of cortisol awakening responses, though this evidence base is smaller for IPT specifically than for CBT.

Oxytocin and Affiliative Neurocircuitry

The oxytocinergic system plays a central role in social bonding, trust, and the regulation of social stress. Intranasal oxytocin studies demonstrate enhanced social perception, reduced amygdala reactivity to social threat, and increased approach behavior. Depression is associated with alterations in oxytocin signaling, particularly in the context of insecure attachment. IPT's focus on repairing attachment relationships and increasing social engagement plausibly activates oxytocin-mediated neural circuits, though direct evidence linking IPT specifically to changes in peripheral or central oxytocin is limited and represents an important research frontier.

Prefrontal-Limbic Circuitry and Emotion Regulation

Neuroimaging studies of psychotherapy response in depression consistently identify changes in the prefrontal cortex (particularly the dorsolateral and ventromedial PFC), anterior cingulate cortex (ACC), amygdala, and insula. A key finding across psychotherapy modalities is increased prefrontal regulation of amygdala reactivity, reflecting enhanced top-down emotion regulation. A seminal study by Brody et al. (2001) and subsequent work by Goldapple et al. (2004) demonstrated that successful IPT and CBT produce overlapping but not identical patterns of regional metabolic change. IPT has been specifically associated with changes in the right prefrontal cortex and insula, regions implicated in social cognition and interoceptive awareness. Martin and colleagues (2015) found that IPT responders showed normalization of amygdala hyperactivity to negative facial expressions, consistent with improved processing of social-emotional stimuli.

Serotonergic, Dopaminergic, and Reward Systems

Social isolation and interpersonal loss reduce dopaminergic signaling in the ventral striatum and nucleus accumbens—key nodes of the brain's reward circuit. This is consistent with the anhedonia and motivational deficits seen in depression following social loss. Serotonin (5-HT) modulates social behavior, aggression, and affiliation; the serotonin transporter gene-linked polymorphic region (5-HTTLPR) moderates the relationship between stressful life events and depression risk, as demonstrated by Caspi et al. (2003), though the specificity of this gene-environment interaction has been debated. IPT's emphasis on re-engagement with social activities and relationships may restore reward circuit function, though this hypothesis awaits direct confirmation through PET or fMRI reward-task paradigms in IPT-treated patients.

Neuroplasticity and BDNF

Brain-derived neurotrophic factor (BDNF), a key mediator of synaptic plasticity, is reduced in the serum of depressed patients and normalized by both antidepressant medication and successful psychotherapy. While most BDNF data in psychotherapy research come from CBT studies, the mechanism is likely transdiagnostic and transtherapeutic. The social engagement and new learning that occur in IPT would be expected to promote hippocampal and prefrontal neuroplasticity via BDNF-dependent pathways.

In summary, IPT's mechanisms likely involve a cascade from improved interpersonal functioning → reduced psychosocial stress → HPA axis normalization and enhanced social reward processing → improved prefrontal-limbic regulation → symptom remission. This model remains partially speculative, and a significant limitation of the IPT evidence base compared to CBT is the relative paucity of mechanistic neuroimaging and biomarker studies.

IPT has one of the strongest evidence bases of any psychotherapy for depression, supported by numerous randomized controlled trials (RCTs), meta-analyses, and inclusion in every major treatment guideline.

Landmark Trials

The foundational evidence for IPT came from the NIMH Treatment of Depression Collaborative Research Program (TDCRP), published in 1989 by Elkin and colleagues. This landmark multisite trial randomized 250 outpatients with MDD to IPT, CBT, imipramine plus clinical management, or placebo plus clinical management over 16 weeks. Key findings: IPT and imipramine were comparably effective for more severely depressed patients (Hamilton Rating Scale for Depression [HRSD] ≥ 20), with recovery rates of approximately 43% for IPT, 42% for CBT, 57% for imipramine, and 29% for placebo. IPT showed a specific advantage over CBT in the more severely depressed subgroup, though the overall pattern suggested comparable efficacy between the two psychotherapies.

The Pittsburgh Maintenance Therapies in Recurrent Depression study (Frank et al., 1990) demonstrated that monthly maintenance IPT (IPT-M) significantly reduced relapse rates compared to placebo over three years, though it was less effective than maintenance imipramine. Specifically, the median survival time without recurrence was 82 weeks for IPT-M versus 45 weeks for placebo and 124 weeks for imipramine maintenance. This study established the role of maintenance IPT for recurrence prevention.

The STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression), while primarily a medication-switching study, is relevant contextually as it highlighted that roughly two-thirds of depressed patients do not remit with first-line pharmacotherapy—underscoring the need for effective psychotherapies like IPT.

Meta-Analytic Evidence

Cuijpers and colleagues have conducted the most comprehensive meta-analyses of IPT for depression. A 2011 meta-analysis of 38 studies found a large effect size for IPT versus control conditions (Hedges' g = 0.63, 95% CI: 0.36–0.90). When compared directly to other active psychotherapies, IPT was not significantly different from CBT (g = 0.06, non-significant), though it was superior to supportive counseling and treatment as usual. A 2016 updated meta-analysis by Cuijpers et al. confirmed these findings and reported response rates for IPT in the range of 50–60% and remission rates of approximately 35–45%, comparable to those seen with antidepressant pharmacotherapy and CBT.

The number needed to treat (NNT) for IPT versus waiting list or usual care for depression response is approximately 3–5, a clinically meaningful figure. Versus active comparators (e.g., clinical management alone), the NNT is larger, approximately 6–10, reflecting the smaller incremental benefit when compared to an active control condition.

Combination Treatment

Several studies have examined IPT combined with antidepressant medication versus either alone. The evidence generally supports a modest additive benefit of combined treatment, particularly for severe or chronic depression. The Keller et al. (2000) CBASP study demonstrated that combining psychotherapy with nefazodone was superior to either alone for chronic depression (though that study used CBASP, not IPT, the principle of combination applies). For IPT specifically, studies by Reynolds et al. (1999) in geriatric depression found that combined nortriptyline + IPT produced the lowest recurrence rates (approximately 20% over three years) compared to either treatment alone or placebo.

Comparison with Pharmacotherapy

Head-to-head trials consistently show that IPT and antidepressant medication produce comparable acute response rates for mild to moderate MDD. For severe depression, the evidence is mixed but generally suggests that pharmacotherapy may have a slight edge in the acute phase, while IPT may produce more enduring effects after treatment discontinuation. A notable advantage of psychotherapy over pharmacotherapy is the sustained response after treatment ends: patients treated with IPT show lower relapse rates in the 12 months following treatment discontinuation compared to patients whose antidepressants are discontinued, suggesting that IPT builds enduring interpersonal skills and coping capacities.

IPT-A: Interpersonal Therapy for Depressed Adolescents

IPT-A was developed by Laura Mufson and colleagues in the 1990s as an adaptation of standard IPT for 12- to 18-year-old adolescents with depression. IPT-A retains the core structure and four problem areas of standard IPT but adds a fifth problem area: single-parent families, reflecting the developmental reality that many depressed adolescents live in non-traditional family structures with specific interpersonal challenges. IPT-A is delivered in 12 sessions and includes adaptations such as greater involvement of parents (in at least one to two sessions), use of developmentally appropriate psychoeducation, and attention to adolescent-specific role transitions (e.g., school transitions, puberty, emerging sexuality, peer group changes).

The evidence base for IPT-A is strong. The landmark Mufson et al. (1999) RCT demonstrated that IPT-A was significantly more effective than clinical monitoring for depressed adolescents, with 75% of IPT-A-treated adolescents meeting criteria for recovery compared to 46% in the control group. A subsequent effectiveness trial in school-based mental health clinics (Mufson et al., 2004) confirmed these findings in a real-world setting, with IPT-A producing significantly greater reductions in depressive symptoms and functional impairment compared to treatment as usual. Effect sizes for IPT-A versus control in adolescent depression are in the moderate to large range (d = 0.50–0.80).

IPT-A has been recognized by the American Academy of Child and Adolescent Psychiatry and the NICE guidelines as an evidence-based treatment for adolescent depression. It is one of only a small number of psychotherapies with strong evidence for this age group, alongside CBT. A notable advantage of IPT-A is its focus on the interpersonal context, which may be more intuitively resonant for adolescents than the cognitive restructuring emphasis of CBT, and which aligns with the developmental salience of peer and family relationships during adolescence.

IPT-G: Interpersonal Therapy in Group Format

IPT-G adapts the individual IPT model for delivery in a group setting, typically with 6–10 participants and one or two therapists over 12–16 sessions. IPT-G retains the core framework—problem areas, interpersonal inventory, communication analysis—but leverages group dynamics to provide a live interpersonal laboratory. Patients practice communication skills, receive feedback from peers, and experience universality (the recognition that others share similar interpersonal struggles). IPT-G is inherently more cost-effective than individual IPT, making it an attractive option for healthcare systems with limited resources.

The evidence for IPT-G is particularly impressive in low- and middle-income countries (LMICs). Bolton et al. (2003) conducted a landmark cluster-randomized trial of group IPT for depression among adults in rural Uganda, delivered by trained lay health workers (not mental health professionals). Results were striking: 93% of individuals who received group IPT no longer met criteria for MDD at the end of treatment, compared to 43% in the control group, producing one of the largest effect sizes ever reported for a psychotherapy trial (d ≈ 1.9). While this effect size likely reflects the severity of the sample and the absence of any prior treatment, it demonstrated the feasibility and efficacy of task-shifted IPT in contexts with minimal mental health infrastructure.

Subsequent trials of IPT-G have been conducted in sub-Saharan Africa, South Asia, and Latin America, with consistently positive results. The WHO has identified group IPT as a scalable intervention for global mental health, and it is included in the WHO's Problem Management Plus (PM+) framework. In high-income countries, IPT-G has shown efficacy comparable to individual IPT in several trials, though the evidence base is smaller.

Other Notable Adaptations

The versatility of IPT has given rise to numerous other adaptations:

• IPT for perinatal depression: Adapted for antepartum and postpartum depression, with emphasis on the role transition to parenthood. RCTs by Spinelli and Endicott (2003) and O'Hara et al. (2000) demonstrated efficacy. Guidelines from ACOG and NICE recommend IPT as a first-line treatment for perinatal depression, particularly when patients prefer to avoid pharmacotherapy during pregnancy and breastfeeding.
• IPT for bipolar disorder (IPSRT): Interpersonal and Social Rhythm Therapy, developed by Ellen Frank, integrates IPT with social rhythm regulation for bipolar disorder. The Pittsburgh Maintenance Therapies study demonstrated that IPSRT in acute treatment followed by any maintenance treatment was associated with longer time to recurrence.
• IPT for eating disorders: IPT has been adapted for bulimia nervosa and binge eating disorder. In the landmark Fairburn et al. (1991) and subsequent studies, IPT was comparably effective to CBT for bulimia at long-term follow-up, though it had a slower onset of action. For binge eating disorder, IPT has shown efficacy in the Wilfley et al. (2002) trial.
• IPT for PTSD, social anxiety disorder, and dysthymia: Adaptations exist with varying levels of evidence, generally less robust than for MDD.

Identifying which patients are most likely to benefit from IPT versus other treatments is a clinically important question. The available evidence points to several prognostic indicators:

Positive Prognostic Factors for IPT

• Clear interpersonal precipitant: Patients whose depressive episode has a clear temporal relationship to an interpersonal event (loss, conflict, transition) tend to respond better to IPT than those with no identifiable interpersonal trigger.
• Problem area of role dispute or role transition: As noted, patients formulated under grief, role disputes, or role transitions generally have better outcomes than those formulated under interpersonal deficits.
• Higher baseline social functioning: Patients with some preserved capacity for social engagement, even if currently depressed, tend to respond better. This makes intuitive sense, as IPT leverages existing interpersonal capacities.
• Higher expectations for treatment: As with most psychotherapies, expectancy effects and therapeutic alliance are significant predictors of outcome. IPT's medical model framing (assigning the sick role, normalizing depression as an illness) may be particularly acceptable to patients who are uncomfortable with a more exploratory or insight-oriented approach.
• Preference for interpersonal focus: Research on patient preference effects, while not specific to IPT, suggests that patients who receive their preferred treatment modality have better outcomes. Patients who identify relational problems as central to their distress may be well-suited to IPT.

Negative Prognostic Factors

• Comorbid personality disorder: While not an absolute contraindication, the presence of a personality disorder—particularly Cluster B disorders—is associated with reduced response to time-limited IPT. IPT's brief format may be insufficient to address entrenched interpersonal patterns associated with personality pathology. However, some adaptations (IPT for borderline personality disorder features) have been explored.
• Interpersonal deficits problem area: As discussed, this formulation is associated with poorer outcomes, likely because the patients' social isolation and skill deficits are more chronic and characterological.
• High cognitive distortion: One intriguing set of findings suggests that patients with high levels of dysfunctional attitudes or cognitive distortions may respond preferentially to CBT rather than IPT, while patients with more intact cognition but interpersonal dysfunction may respond better to IPT. This prescriptive matching hypothesis, explored in the context of the NIMH TDCRP and subsequent moderator analyses, has clinical plausibility but requires replication.
• Chronic depression (duration >2 years): Standard 16-session IPT was found to be less effective for chronic depression compared to acute depression, leading to the development of longer-term or combined treatment models for this population.
• Comorbid substance use disorders: Active substance use disorders complicate any psychotherapy and reduce IPT response rates, though adapted models exist.

Importantly, few definitive prescriptive predictors exist that reliably direct clinicians to choose IPT over CBT for a given individual. The Personalized Advantage Index (PAI) approach, developed by DeRubeis and colleagues, represents a promising statistical methodology for generating individualized treatment recommendations, but this work is in its early stages for IPT specifically.

Depression rarely occurs in isolation. The presence of comorbid conditions significantly affects treatment planning, prognosis, and the adaptation of IPT techniques.

Anxiety Disorders

Comorbid anxiety disorders are present in an estimated 50–60% of MDD patients (Kessler et al., 2003; NCS-R data). Generalized anxiety disorder, social anxiety disorder, and panic disorder are the most common co-occurring conditions. IPT does not directly target anxiety symptoms through exposure or cognitive restructuring, yet depressed patients with comorbid anxiety frequently improve on anxiety measures as depression remits—a finding consistent with the shared underlying emotional dysregulation. However, patients with primary social anxiety may present with interpersonal avoidance that complicates the social engagement goals of IPT. Markowitz et al. (2014) conducted a pilot trial of IPT adapted for social anxiety disorder with promising results, though CBT with exposure remains the gold-standard treatment for social anxiety.

Personality Disorders

Comorbid personality disorders are present in approximately 30–50% of patients with MDD, depending on assessment method. As noted, personality pathology is associated with poorer IPT outcomes, particularly when it manifests as chronic interpersonal dysfunction (e.g., borderline, avoidant, or dependent personality features). The interpersonal deficits problem area frequently overlaps with personality disorder features. Clinical wisdom suggests that the time-limited structure of IPT may be insufficient for deeply entrenched relational patterns, and that these patients may benefit from longer-term or integrated treatment approaches.

Medical Comorbidity

IPT has been adapted for depression in the context of various medical illnesses, including HIV/AIDS, cardiovascular disease, cancer, and chronic pain. The role transition framework is particularly well-suited to the adjustment challenges posed by medical diagnosis. Markowitz et al. (1998) demonstrated the efficacy of IPT for depressed HIV-positive patients. In cardiac patients, the ENRICHD trial (2003) tested CBT (not IPT) for post-MI depression, but the role transition and social support elements of IPT make it a theoretically strong candidate for this population.

Substance Use Disorders

Approximately 20–30% of individuals with MDD have a co-occurring substance use disorder (SUD). Active substance use complicates IPT by impairing social cognition, disrupting interpersonal functioning, and creating competing treatment priorities. Modified IPT protocols for patients with concurrent depression and SUD exist but have limited evidence. Generally, clinical guidelines recommend stabilization of substance use before or concurrent with IPT initiation for depression.

Eating Disorders

Given IPT's demonstrated efficacy for bulimia nervosa and binge eating disorder, the comorbidity of depression with eating pathology represents a population for which IPT is uniquely suited. The interpersonal model posits that eating disorder behaviors function as maladaptive coping with interpersonal distress, and addressing the underlying interpersonal issues reduces both depressive and eating disorder symptoms.

While IPT was developed specifically for MDD as defined by DSM criteria, several diagnostic nuances warrant attention in clinical practice:

MDD versus Persistent Depressive Disorder (Dysthymia)

DSM-5-TR distinguishes MDD (episodic, ≥2 weeks) from Persistent Depressive Disorder (PDD, formerly dysthymia; chronic, ≥2 years). Standard acute IPT was developed for episodic MDD and has its strongest evidence for this condition. PDD patients, whose chronic low mood often becomes ego-syntonic and intertwined with personality and interpersonal functioning, may require longer treatment. Markowitz (1998) adapted IPT for dysthymia (IPT-D) with 16–20 sessions and found it effective compared to supportive psychotherapy, though less effective than combined medication + IPT. The Kocsis et al. (2009) REVAMP study found that for chronic depression unresponsive to initial medication, adding CBASP (a related interpersonal therapy) was more effective than adding IPT or supportive therapy, though methodological questions limit the interpretability of this finding.

Bipolar Depression

Standard IPT is not indicated for bipolar depression without modification. IPSRT (Interpersonal and Social Rhythm Therapy) adds a social rhythm regulation component—stabilizing daily routines (sleep, meals, activity) to prevent mood episodes triggered by circadian disruption. Misdiagnosis of bipolar depression as MDD is a well-known clinical pitfall; clinicians using IPT should conduct careful screening for past hypomanic or manic episodes, as standard IPT's activation strategies could theoretically precipitate mania in undiagnosed bipolar patients.

Adjustment Disorder versus MDD

IPT's interpersonal framework is intuitively well-suited to adjustment disorders with depressed mood, which by definition arise in response to identifiable stressors. However, the evidence base for IPT in adjustment disorders is minimal, and clinicians should be cautious about conflating the role transition framework with the broader diagnosis. Patients meeting criteria for adjustment disorder may benefit from abbreviated or less intensive IPT-based interventions.

Prolonged Grief Disorder

As noted, DSM-5-TR now includes PGD as a distinct diagnosis, separate from MDD. While IPT's grief problem area addresses bereavement-related depression, PGD may require the more specialized approach of Complicated Grief Treatment (CGT), which incorporates elements of both IPT and exposure therapy. Clinicians should distinguish between grief-triggered depression (appropriate for IPT) and PGD as a primary condition (which may require CGT).

Despite IPT's robust evidence base, several important limitations and active areas of investigation remain:

Mechanisms of Change

One of the most significant gaps in the IPT literature is the limited understanding of specific mechanisms of change. While it is clear that IPT works, the question of how it works—and whether its effects are mediated by specific interpersonal changes or by nonspecific therapeutic factors (alliance, empathy, validation)—remains incompletely answered. Lipsitz and Markowitz (2013) have argued that IPT's mechanisms likely involve improved attachment security, enhanced social support, and resolution of interpersonal stress, but rigorous mediation studies are rare. This is in contrast to CBT, where cognitive change has been more extensively studied as a mediator.

Neuroimaging Research

As discussed, the neuroimaging literature on IPT is substantially thinner than that on CBT. Few studies have directly compared the neural effects of IPT versus CBT or medication, and most existing studies have small samples. This is a critical gap, as understanding the distinct neural targets of IPT would inform treatment matching and combination strategies.

Digital and Remote Delivery

The COVID-19 pandemic accelerated interest in teletherapy-delivered IPT. Preliminary evidence suggests that IPT can be effectively delivered via videoconference, though large RCTs are needed. Internet-based IPT programs are in development but lag behind the more extensive evidence for internet-based CBT (iCBT). The relational focus of IPT may make it uniquely sensitive to the therapeutic frame—being in the same room may matter more for IPT than for more structured, skill-based therapies.

Transdiagnostic Applications

There is growing interest in whether IPT's interpersonal framework can be applied transdiagnostically—to conditions unified by interpersonal distress, regardless of specific diagnosis. This aligns with the Research Domain Criteria (RDoC) framework, which emphasizes dimensional constructs (such as social affiliation and attachment) over categorical diagnoses. Early adaptations for PTSD, social anxiety, and body dysmorphic disorder are in various stages of investigation.

Task-Shifting and Global Mental Health

One of IPT's most promising frontiers is its scalability through task-shifting—training lay health workers, teachers, or community volunteers to deliver simplified IPT protocols. The Bolton Uganda trial (2003) was the proof of concept, and subsequent implementations in Kenya, Pakistan, Nepal, and Haiti have demonstrated feasibility. The Friendship Bench project in Zimbabwe, while using a different therapeutic framework, shares the task-shifting principle that IPT-G has pioneered. The challenge remains quality control, supervision, and adaptation to diverse cultural contexts.

Precision Medicine and Treatment Matching

The ultimate goal is to predict which individual patient will respond best to IPT versus CBT versus medication. Machine learning approaches to baseline clinical, demographic, and biological data are being explored (e.g., the PAI approach). Genetic moderators—such as the 5-HTTLPR polymorphism, FKBP5 variants, and OXTR gene polymorphisms—are theoretically relevant to differential IPT response, but empirical evidence is sparse.

Limitations of the Evidence Base

Key limitations include: (1) Most IPT trials have been conducted in high-income, Western countries, limiting generalizability (though the LMIC literature is growing). (2) The number of head-to-head comparisons with active treatments is smaller than for CBT. (3) Long-term follow-up data (beyond 1–2 years) are limited. (4) Allegiance effects—the tendency for treatments to perform better in trials conducted by their developers—may inflate some IPT effect sizes. (5) The interpersonal deficits problem area remains poorly defined and underresearched.

Interpersonal Therapy (IPT) is a well-established, empirically supported psychotherapy for major depressive disorder, with a strong evidence base across age groups, clinical settings, and cultural contexts. Its core strengths include: a clear, teachable structure organized around four problem areas; demonstrated efficacy comparable to CBT and antidepressant medication for mild to moderate depression; strong evidence for maintenance treatment to prevent recurrence; successful adaptations for adolescents (IPT-A), group settings (IPT-G), perinatal depression, and eating disorders; and unparalleled scalability for global mental health through task-shifting.

Clinicians should consider IPT particularly for patients with: a clear interpersonal precipitant for their depressive episode; a preference for a relationally focused rather than cognitively focused therapy; perinatal depression where pharmacotherapy avoidance is desired; recurrent depression requiring maintenance treatment; and in contexts where group delivery can improve access to care.

IPT may be less optimal for patients with: chronic depression without a clear interpersonal focus; severe personality pathology requiring longer-term treatment; conditions where exposure-based treatment is indicated (e.g., primary anxiety disorders, PTSD); and active substance use disorders that have not been stabilized.

The field would benefit from: more mechanistic research, including neuroimaging and biomarker studies; larger head-to-head trials comparing IPT to CBT with adequate statistical power for moderator analyses; development of validated treatment matching algorithms; and rigorous evaluation of digital and teletherapy IPT delivery models. Despite these gaps, IPT's contribution to the evidence-based psychotherapy landscape is substantial and enduring.